Literature DB >> 10268553

The Food and Drug Administration algorithm. Special workshop--regulatory.

W M Turner.   

Abstract

The Food and Drug Administration presently receives and evaluates over 40,000 case reports of adverse drug effects a year. Each report is objectively reviewed and evaluated. A causal association assessment between each drug and reaction is made. The objective causal assessments are based on four basic principles: (a) temporal eligibility, (b) dechallenge and outcome, (c) rechallenge and outcome, and (d) confounding factors. This presentation introduces the algorithm used by the FDA Division of Drug Experience and provides the basic information needed to use the FDA algorithm for making causal relationship assessments.

Mesh:

Year:  1984        PMID: 10268553     DOI: 10.1177/009286158401800311

Source DB:  PubMed          Journal:  Drug Inf J        ISSN: 0092-8615


  12 in total

1.  Comparison of three pharmacovigilance algorithms in the ICU setting: a retrospective and prospective evaluation of ADRs.

Authors:  Sandra L Kane-Gill; Elizabeth A Forsberg; Margaret M Verrico; Steven M Handler
Journal:  Drug Saf       Date:  2012-08-01       Impact factor: 5.606

Review 2.  Methods for causality assessment of adverse drug reactions: a systematic review.

Authors:  Taofikat B Agbabiaka; Jelena Savović; Edzard Ernst
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.

Authors:  Saibal Das; Sapan K Behera; Alphienes S Xavier; Srinivas Velupula; Steven A Dkhar; Sandhiya Selvarajan
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

4.  Side effects of ofloxacin in clinical trials and in postmarketing surveillance.

Authors:  G Jüngst; R Mohr
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Hepatotoxicity induced by trimethoprim-sulfamethoxazole in a child with cystic fibrosis.

Authors:  Ibrahim Abdulhamid; Victoria Tutag Lehr
Journal:  J Pediatr Pharmacol Ther       Date:  2014-01

6.  Defining and measuring meditation-related adverse effects in mindfulness-based programs.

Authors:  Willoughby B Britton; Jared R Lindahl; David J Cooper; Nicholas K Canby; Roman Palitsky
Journal:  Clin Psychol Sci       Date:  2021-11-01

7.  Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool.

Authors:  Ruairi M Gallagher; Jamie J Kirkham; Jennifer R Mason; Kim A Bird; Paula R Williamson; Anthony J Nunn; Mark A Turner; Rosalind L Smyth; Munir Pirmohamed
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

8.  The varieties of contemplative experience: A mixed-methods study of meditation-related challenges in Western Buddhists.

Authors:  Jared R Lindahl; Nathan E Fisher; David J Cooper; Rochelle K Rosen; Willoughby B Britton
Journal:  PLoS One       Date:  2017-05-24       Impact factor: 3.240

9.  Levetiracetam-induced rage and suicidality: Two case reports and review of literature.

Authors:  Orakwue A Molokwu; Birinus A Ezeala-Adikaibe; Ikenna O Onwuekwe
Journal:  Epilepsy Behav Case Rep       Date:  2015-08-28

10.  A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions.

Authors:  Mahesh N Belhekar; Santosh R Taur; Renuka P Munshi
Journal:  Indian J Pharmacol       Date:  2014 Jan-Feb       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.